Addex Therapeutics Ltd (CH:ADXN) has released an update.
Addex Therapeutics has reported that their Phase 2 epilepsy study of ADX71149 did not meet its primary endpoint, though it was found to be safe and well tolerated. The company, in collaboration with Janssen Pharmaceuticals, is analyzing the full data set to determine the future of the ADX71149 program. Additionally, Addex is progressing with its GABAB PAM collaboration with Indivior, targeting drug candidates for substance use disorder and chronic cough.
For further insights into CH:ADXN stock, check out TipRanks’ Stock Analysis page.
